{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T16:36:31Z","timestamp":1726763791953},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.trim.2024.102079","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T09:01:06Z","timestamp":1719910866000},"page":"102079","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prior to ABOi liver transplant with PD-1 inhibitor in patients with hepatocellular carcinoma: A case report"],"prefix":"10.1016","volume":"85","author":[{"given":"Yipeng","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jicheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanbang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangbo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2024.102079_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl. 2","key":"10.1016\/j.trim.2024.102079_bb0010","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1002\/lt.22365","article-title":"Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience","volume":"17","author":"Mazzaferro","year":"2011","journal-title":"Liver Transpl."},{"key":"10.1016\/j.trim.2024.102079_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2021.100606","article-title":"Downstaging treatment for patients with hepatocelluar carcinoma before transplantation","volume":"35","author":"Jiang","year":"2021","journal-title":"Transplant. Rev. (Orlando)"},{"key":"10.1016\/j.trim.2024.102079_bb0020","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(11)70175-9","article-title":"Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report","volume":"13","author":"Clavien","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trim.2024.102079_bb0025","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ajt.15617","article-title":"Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?","volume":"20","author":"Nordness","year":"2020","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2024.102079_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101386","article-title":"Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period","volume":"66","author":"Chen","year":"2021","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.trim.2024.102079_bb0035","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/hep.31234","article-title":"Immunotherapy as a Downstaging therapy for liver transplantation","volume":"72","author":"Schwacha-Eipper","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.trim.2024.102079_bb0040","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.transproceed.2013.11.100","article-title":"Fourteen successful consecutive cases of ABO-incompatible living donor liver transplantation: new simplified intravenous immunoglobulin protocol without local infusion therapy","volume":"46","author":"Kim","year":"2014","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2024.102079_bb0045","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.3390\/curroncol29120771","article-title":"Immunotherapy use prior to liver transplant in patients with hepatocellular carcinoma","volume":"29","author":"Woo","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.trim.2024.102079_bb0050","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/ajt.16448","article-title":"PD-1 inhibitor as bridge therapy to liver transplantation?","volume":"21","author":"Tabrizian","year":"2021","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2024.102079_bb0055","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.transproceed.2005.03.148","article-title":"New protocol of immunosuppression for liver transplantation across ABO barrier: the use of rituximab, hepatic arterial infusion, and preservation of spleen","volume":"37","author":"Yoshizawa","year":"2005","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2024.102079_bb0060","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/08830185.2019.1601720","article-title":"ABO-incompatible liver transplantation - a review of the historical background and results","volume":"38","author":"Dahlgren","year":"2019","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.trim.2024.102079_bb0065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ajt.13444","article-title":"ABO-incompatible adult living donor liver transplantation under the desensitization protocol with rituximab","volume":"16","author":"Song","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2024.102079_bb0070","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/ajt.14448","article-title":"Dual-graft adult living donor liver transplantation with ABO-incompatible graft: short-term and long-term outcomes","volume":"18","author":"Kwon","year":"2018","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2024.102079_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.594558","article-title":"Sintilimab: a promising anti-tumor PD-1 antibody","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327424000959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327424000959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T19:10:32Z","timestamp":1721416232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327424000959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":15,"alternative-id":["S0966327424000959"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2024.102079","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prior to ABOi liver transplant with PD-1 inhibitor in patients with hepatocellular carcinoma: A case report","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2024.102079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102079"}}